This Day On The Street
Continue to site right-arrow
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
TheStreet Open House

Royalty Pharma Posts Further Revised Offer Document In Offer For Elan Corporation, Plc ("Elan")

Stocks in this article: ELN

NEW YORK, June 10, 2013 /PRNewswire/ -- Following its announcement on 7 June 2013, Echo Pharma Acquisition Limited ("Royalty Pharma") has today issued a further revised offer document dated 10 June 2013 (the "Further Revised Offer Document"). In the Further Revised Offer Document, Royalty Pharma confirms the Offer Price for Elan Corporation, plc (NYSE: ELN) set forth in its Rule 2.5 Announcement of 7 June 2013 (please see the Further Revised Offer Document for details).

The Offer Price comprises $13.00 per share in cash plus a contingent value right ("CVR") worth up to $2.50 per share upon the achievement of certain CVR Payment Events. The CVR, based on feedback from Elan Stockholders, enables participation in any future upside of Tysabri including approval in secondary progressive multiple sclerosis and the achievement of certain sales milestones that are detailed further in the Further Revised Offer Document.

The Further Revised Offer Document which contains, amongst other things, the full terms of, and the conditions to, the Offer is being posted to Elan Shareholders today together with the Further Revised Form of Acceptance and will be available at www.royaltypharma.com.

The Offer will remain open for acceptance until 1:00 p.m. (Irish time) / 8:00 a.m. ( New York City time) on Monday, 24 June 2013 and will remain open for acceptance until that time. Full details of the procedure for accepting the Offer are set out in the Further Revised Offer Document.

Royalty Pharma hopes Elan shareholders will give Royalty Pharma's Further Increased Offer careful consideration.

Sincerely,

Pablo Legorreta

A copy of the Further Revised Offer Document is available for inspection at the offices of Matheson, 70 Sir John Rogerson's Quay, Dublin 2, Ireland.

Definitions used in the Further Revised Offer Document have the same meaning when used in this announcement, unless the context requires otherwise.

J.P. Morgan, together with its affiliate J.P. Morgan Cazenove, BofA Merrill Lynch, together with its affiliate Merrill Lynch International, Groton Partners and Investec are acting as financial advisers to Royalty Pharma.

1 of 6

Check Out Our Best Services for Investors

Action Alerts PLUS

Jim Cramer and Stephanie Link reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

Jim Cramer's protégé, David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
Try it NOW
Try it NOW
Try it NOW

Check Out Our Best Services for Investors

Dividend Stock Advisor

Jim Cramer's protégé, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Options Profits

Our options trading pros provide over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • Actionable options commentary and news
  • Real-time trading community
Try it NOW
Try it NOW
Try it NOW
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!

Markets

DOW 17,191.37 -195.84 -1.13%
S&P 500 2,002.16 -27.39 -1.35%
NASDAQ 4,637.9940 -43.5030 -0.93%

Partners Compare Online Brokers

Free Reports

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs